CD19 Antibody (FMC63) [DyLight 488] Summary
Additional Information |
Recombinant Monoclonal Antibody. Clone FMC63 was used by HLDA to establish CD designation. |
Immunogen |
Human prolymphocytic leukaemia cell line JVM3. |
Isotype |
IgG2a Kappa |
Clonality |
Monoclonal |
Host |
Mouse |
Gene |
CD19 |
Purity |
Protein A purified |
Innovator's Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase. |
Applications/Dilutions
Dilutions |
- CyTOF-ready
- ELISA
- Flow Cytometry
- Immunocytochemistry/ Immunofluorescence
- Immunohistochemistry
- Immunohistochemistry-Paraffin
|
Application Notes |
Optimal dilution of this antibody should be experimentally determined. |
Reactivity Notes
Packaging, Storage & Formulations
Storage |
Store at 4C in the dark. |
Buffer |
50mM Sodium Borate |
Preservative |
0.05% Sodium Azide |
Purity |
Protein A purified |
Notes
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
Alternate Names for CD19 Antibody (FMC63) [DyLight 488]
Background
CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, is a type 1 transmembrane glycoprotein belonging to immunoglobulin (Ig) subfamily that serves as a biomarker for normal and neoplastic B cells (1,2). CD19 is a co-receptor for the B cell receptor (BCR) signaling complex and has a critical role in regulating B cell signaling and immune response (1,2). The CD19 protein contains an extracellular N-terminus containing two C2 Ig-like domains separated by a helical non-Ig domain, a single pass transmembrane domain, and a highly conserved cytoplasmic C-terminal domain (1,2). The human CD19 protein, encoded by the CD19 gene located on chromosome 16p11.2, is 556 amino acids (aa) in length with a calculated theoretical molecular weight (MW) of 61 kDa and an observed molecular weight of 95 kDa (1-3). CD19 associates with other molecules - CD21, CD81, and CD225 - to form the BCR co-complex, also called the CD19 complex, through CD21 binding to the complement C3d complex (1-3). Complement C3d bridges the BCR with the CD19 complex into lipid rafts of the plasma membrane (1-3). CD19 is capable of modulating B cell development through both BCR-dependent and -independent signaling (1-3). Upon BCR activation, the tyrosine residues of CD19's cytoplasmic tail recruits multiple kinases including Lyn, Vav, and PI3K, amplifying BCR-mediated immune signaling and B cell activation (1-3).
Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).
References
1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36
2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010
3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017
4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208
5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445
6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are
guaranteed for 1 year from date of receipt.
Customers Who Viewed This Item Also Viewed...
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Ca, Hu, Mu, Po
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, KD
Species: Hu, Mu
Applications: Flow, WB
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
Species: Hu, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, IP, WB
Species: Hu
Applications: BA
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), IHC, IP, WB
Species: Hu
Applications: CyTOF-ready, Flow, IMC, ICC/IF, IHC, IHC-P, WB
Species: Mu
Applications: CyTOF-ready, Flow, ICC, IHC, WB
Species: Rt
Applications: IHC, WB
Species: Ca, Hu, Pm, Mu, Rt
Applications: ICC/IF, WB
Species: Hu, Mu
Applications: CyTOF-ready, Flow, ICC, KO, Simple Western, WB
Species: Hu
Applications: BA
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Mu
Applications: ELISA
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ICC/IF, IHC, IHC-P
Publications for CD19 Antibody (NBP2-52716G) (0)
There are no publications for CD19 Antibody (NBP2-52716G).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for CD19 Antibody (NBP2-52716G) (0)
There are no reviews for CD19 Antibody (NBP2-52716G).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
Video Protocols
FAQs for CD19 Antibody (NBP2-52716G) (0)